Abstract
We examined whether demographic and tumour characteristics (including subtype) were different for women with breast cancer diagnosed via mammography screening compared with women with interval breast cancers, lapsed attenders of the screening programme and non-participants of the screening programme. In addition, we explored whether there were survival differences between the groups, taking into account lead time bias. We used linked data from National Cancer Registry Ireland and the national breast screening programme BreastCheck. Multinomial logistic regression was used to test the association of covariates with screening status. For survival analysis, we corrected the survival time for screen-detected cases for lead time bias, examined Kaplan-Meier curves and then used Cox regression to investigate differences in survival by screening status. Subtype (HER2 over-expressing, triple negative), stage (III/IV), grade (poor), having co-morbidities, area of deprivation, smoking status and age were associated with having interval cancer or being a non-participant of the screening programme in the multivariable model. After correcting for lead time bias, and adjusting for variables associated with screening status, there was no evide...Continue Reading
References
Jul 1, 1997·Nursing Outlook
Apr 17, 1999·British Journal of Cancer·D H BrewsterD J Goldberg
Aug 13, 1999·Journal of Medical Screening·A R AroM Schreck
Aug 16, 2000·Radiologic Clinics of North America·L TabárR A Smith
Jan 5, 2002·Breast Cancer Research and Treatment·A R AroM Schreck
Apr 9, 2005·Journal of Medical Screening·Sven TörnbergAntonio Ponti
Oct 24, 2007·The Journal of Surgical Research·Chukwuemeka U IhemelanduWayne A Frederick
May 5, 2011·British Journal of Cancer·P C AllgoodG Lawrence
Jun 29, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A GoldhirschUNKNOWN Panel members
Nov 2, 2011·Breast Cancer Research and Treatment·Jiyoung KimJung-Hyun Yang
Nov 3, 2012·Lancet·UNKNOWN Independent UK Panel on Breast Cancer Screening
Jan 31, 2013·Breast Cancer Research : BCR·Marina PollánRoberto Pastor-Barriuso
Jun 6, 2013·The Cochrane Database of Systematic Reviews·Peter C Gøtzsche, Karsten Juhl Jørgensen
May 8, 2014·Journal of Medical Screening·C CoyleD O'Reilly
Jun 22, 2014·BMJ : British Medical Journal·Harald Weedon-FekjærLars J Vatten
Oct 28, 2014·Breast Cancer Research : BCR·Norman F BoydSalomon Minkin
Nov 6, 2014·PloS One·Paul M WalshHarry Comber
Apr 29, 2015·Journal of Medical Screening·Katie M O'BrienHarry Comber
Sep 1, 2015·Cancer Epidemiology·Marianna de Camargo CancelaLinda Sharp
Oct 27, 2015·JAMA : the Journal of the American Medical Association·Evan R MyersGillian D Sanders
Nov 5, 2015·Breast Cancer Research and Treatment·Marisa BaréMaria Sala
Nov 13, 2015·International Journal of Cancer. Journal International Du Cancer·Archie BleyerAnthony B Miller
Nov 20, 2015·Journal of Medical Screening·Solveig HofvindLars Akslen
Jun 17, 2016·Journal of Medical Screening·Lennarth NyströmJan Frisell
May 1, 2017·Clinical Breast Cancer·Gabriele BellioMarina Bortul
Dec 21, 2017·PloS One·James A HanleyKatie M O'Brien
Citations
Feb 20, 2020·JAMA Surgery·Yalei ChenLisa A Newman
May 10, 2019·Journal of Medical Screening·Ross LawrensonIan Campbell
Jul 18, 2020·JCO Global Oncology·Neslihan CabioğluVahit Özmen
Nov 20, 2019·Aging·Guanming LuJie Li
Aug 1, 2020·Frontiers in Oncology·Xinya GaoJie Li
Nov 22, 2020·BMC Cancer·Henry G KaplanMary K Atwood
Jan 10, 2021·Breast Cancer Research and Treatment·Johanna AlankoJorma Isola
May 18, 2021·Frontiers in Oncology·Kunlong LiCan Zhou
Sep 1, 2021·Cancer Medicine·Anne Marie McCarthyKatrina Armstrong
Nov 25, 2021·Cancer Causes & Control : CCC·Marta Hernández-GarcíaDolores Salas
Jan 14, 2022·Breast Cancer Research and Treatment·Genevieve A FasanoLisa Newman